Gisele Nishiguchi

TL;DR: Investigations suggest that the pyrazole triols prefer to bind to ERalpha with their C(3)-phenol in the estradiol A-ring binding pocket and that binding selectivity results from differences in the interaction of thePyrazole core and C(4)-propyl group with portions of the receptor where ERalpha has a smaller residue than ERbeta.

TL;DR: In this article, new compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided, where the new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine- mediated disorder, such as cancer.

TL;DR: The synthesis, in vitro activity, in vivo activity in an acute myeloid leukemia xenograft model, and preclinical profile of the potent and selective pan PIM kinase inhibitor compound 8 (PIM447) are described.

TL;DR: In this article, the authors provided compounds of Formula (I) and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity, and compositions comprising these compounds and a therapeutic co-agent.

TL;DR: In this article, a compound of Formula (I): and pharmaceutically acceptable salts thereof, as further described in this paper, are presented. And formulations comprising compounds of formula I, and a method to use such compounds for treating a disease or condition mediated by Provirus Integration of Maloney Maloney Kinase (PIM Kinase), GSK3, PKC, KDR, PDGFRa, FGFR3, FLT3, or cABL.